Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lupus drug continuation trial offers hope for disease control

NCT ID NCT06875960

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being enrolled, all of whom have already shown benefit from the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
deucravacitinib
What this could lead to
If successful, this could provide a long-term treatment option to control lupus symptoms and reduce flare-ups.
What could go wrong
This is a small continuation study with only 35 participants, so results may not apply to all lupus patients. Risks include potential side effects from long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

discoid lupus erythematosus subacute cutaneous lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (DLE/SCLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

  • Local Institution - 0001

    WITHDRAWN

    Farmington, Connecticut, 06030, United States

  • Local Institution - 0003

    WITHDRAWN

    Jackson, Tennessee, 38305, United States

  • New York University School Of Medicine

    RECRUITING

    New York, New York, 10155, United States

  • Oklahoma Medical Research Foundation

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.